KR101978537B1 - Tor 키나제 억제제를 사용한 암의 치료 - Google Patents

Tor 키나제 억제제를 사용한 암의 치료 Download PDF

Info

Publication number
KR101978537B1
KR101978537B1 KR1020147012908A KR20147012908A KR101978537B1 KR 101978537 B1 KR101978537 B1 KR 101978537B1 KR 1020147012908 A KR1020147012908 A KR 1020147012908A KR 20147012908 A KR20147012908 A KR 20147012908A KR 101978537 B1 KR101978537 B1 KR 101978537B1
Authority
KR
South Korea
Prior art keywords
substituted
pyrazin
unsubstituted
tor kinase
kinase inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147012908A
Other languages
English (en)
Korean (ko)
Other versions
KR20140092336A (ko
Inventor
수이찬 수
크리스텐 마에 헤게
안토니아 로페즈-히로나
헤더 레이몬
라마 케이. 나를라
라제쉬 초프라
Original Assignee
시그날 파마소티칼 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그날 파마소티칼 엘엘씨 filed Critical 시그날 파마소티칼 엘엘씨
Publication of KR20140092336A publication Critical patent/KR20140092336A/ko
Application granted granted Critical
Publication of KR101978537B1 publication Critical patent/KR101978537B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020147012908A 2011-10-19 2012-10-18 Tor 키나제 억제제를 사용한 암의 치료 Active KR101978537B1 (ko)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201161549034P 2011-10-19 2011-10-19
US61/549,034 2011-10-19
US201261591401P 2012-01-27 2012-01-27
US61/591,401 2012-01-27
US201261647233P 2012-05-15 2012-05-15
US61/647,233 2012-05-15
US201261653436P 2012-05-31 2012-05-31
US61/653,436 2012-05-31
PCT/US2012/060723 WO2013059396A2 (en) 2011-10-19 2012-10-18 Treatment of cancer with tor kinase inhibitors

Publications (2)

Publication Number Publication Date
KR20140092336A KR20140092336A (ko) 2014-07-23
KR101978537B1 true KR101978537B1 (ko) 2019-05-14

Family

ID=47116477

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147012908A Active KR101978537B1 (ko) 2011-10-19 2012-10-18 Tor 키나제 억제제를 사용한 암의 치료

Country Status (19)

Country Link
US (4) US9493466B2 (cg-RX-API-DMAC7.html)
EP (3) EP3466423B1 (cg-RX-API-DMAC7.html)
JP (5) JP2014530861A (cg-RX-API-DMAC7.html)
KR (1) KR101978537B1 (cg-RX-API-DMAC7.html)
CN (2) CN103998036B (cg-RX-API-DMAC7.html)
BR (1) BR112014009755B1 (cg-RX-API-DMAC7.html)
CA (1) CA2852921C (cg-RX-API-DMAC7.html)
EA (2) EA034512B1 (cg-RX-API-DMAC7.html)
ES (2) ES2894958T3 (cg-RX-API-DMAC7.html)
IL (3) IL232128B (cg-RX-API-DMAC7.html)
IN (1) IN2014CN02887A (cg-RX-API-DMAC7.html)
MX (4) MX373925B (cg-RX-API-DMAC7.html)
MY (1) MY183661A (cg-RX-API-DMAC7.html)
PH (1) PH12014500869A1 (cg-RX-API-DMAC7.html)
SG (3) SG10201912850WA (cg-RX-API-DMAC7.html)
TW (4) TWI758746B (cg-RX-API-DMAC7.html)
UA (1) UA115319C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013059396A2 (cg-RX-API-DMAC7.html)
ZA (2) ZA201402771B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299248B2 (en) 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
ES2638179T3 (es) 2013-01-16 2017-10-19 Signal Pharmaceuticals, Llc Compuestos de pirrolopirimidina sustituidos, composiciones de los mismos, y métodos de tratamiento con los mismos
AU2014223501A1 (en) * 2013-02-28 2015-09-17 Signal Pharmaceuticals, Llc Treatment of cancer with TOR kinase inhibitors
KR20160002792A (ko) * 2013-04-17 2016-01-08 시그날 파마소티칼 엘엘씨 암 치료용 tor 키나제 억제제 및 n-(3-(5-플루오로-2-(4-(2-메톡시에톡시)페닐아미노)피리미딘-4-일아미노)페닐)아크릴아미드를 포함하는 병용 요법
HK1221150A1 (zh) 2013-04-17 2017-05-26 西格诺药品有限公司 用二氢吡嗪并-吡嗪类对癌症的治疗
US9474757B2 (en) * 2013-04-17 2016-10-25 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy
US9937169B2 (en) * 2013-04-17 2018-04-10 Signal Pharmaceuticals, Llc Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
MX374749B (es) 2013-04-17 2025-03-06 Signal Pharm Llc Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer.
WO2014172425A1 (en) * 2013-04-17 2014-10-23 Signal Pharmaceuticals, Llc Treatment of cancer with dihydropyrazino-pyrazines
CN105358177B (zh) * 2013-04-17 2018-11-23 西格诺药品有限公司 包含tor激酶抑制剂和imid化合物的联合疗法用于治疗癌症
SG11201508527VA (en) 2013-04-17 2015-11-27 Signal Pharm Llc Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl) pyridin-3-yl) -3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one
CA2912627C (en) 2013-05-29 2022-03-15 Signal Pharmaceuticals, Llc Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, a solid form thereof and methods of their use
CN105792816A (zh) * 2013-10-04 2016-07-20 西格诺药品有限公司 以基因突变为特征的癌症的预防或治疗中的tor激酶抑制剂
WO2015160882A1 (en) 2014-04-16 2015-10-22 Signal Pharmaceuticals, Llc SOLID FORMS COMPRISING 7-(6-(2-HYDROXYPROPAN-2YL) PYRIDIN-3-YL)-1-(TRANS)-4-METHOXYCYCLOHEXYL)-3, 4-DIHYDROPYRAZINO[2,3-b] PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
US9512129B2 (en) 2014-04-16 2016-12-06 Signal Pharmaceuticals, Llc Solid forms comprising 1-ethyl-7-(2-methyl-6-(1H-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one and a coformer
NZ714742A (en) 2014-04-16 2017-04-28 Signal Pharm Llc Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use
JP2017514806A (ja) 2014-04-16 2017-06-08 シグナル ファーマシューティカルズ，エルエルシー Ｔｏｒキナーゼ阻害剤組み合わせ療法を使用して癌を治療する方法
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
CN106715427A (zh) 2014-07-14 2017-05-24 西格诺药品有限公司 利用取代的吡咯并嘧啶化合物、其组合物治疗癌症的方法
KR102708936B1 (ko) 2015-11-20 2024-09-25 포르마 세라퓨틱스 인크. 유비퀴틴-특이적 프로테아제 1 억제제로서의 퓨리논
WO2017136689A1 (en) * 2016-02-05 2017-08-10 Academia Sinica Purine compounds possessing anticancer activity
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
PE20191474A1 (es) 2016-12-20 2019-10-16 Astrazeneca Ab Compuestos de amino-triazolopiridina y su uso en el tratamiento del cancer
KR102795129B1 (ko) 2017-06-22 2025-04-15 셀진 코포레이션 B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
US20210254000A1 (en) * 2017-11-01 2021-08-19 Juno Therapeutics, Inc. Process for producing a t cell composition
HRP20250517T1 (hr) 2018-03-09 2025-06-20 Recurium Ip Holdings, Llc Supstituirani 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-oni
CN110526907B (zh) * 2018-05-23 2021-04-23 四川大学 苯并噁嗪酮类衍生物及其应用
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
CN119431323A (zh) 2019-07-31 2025-02-14 贝林格尔·英格海姆国际有限公司 作为cd38抑制剂的杂双环酰胺
TWI768550B (zh) * 2019-11-22 2022-06-21 大陸商南京明德新藥研發有限公司 作為dna-pk抑制劑的嘧啶并吡咯類螺環化合物及其衍生物
JP7383818B2 (ja) * 2019-11-25 2023-11-20 ザイ ラボ （シャンハイ） カンパニー、リミテッド． Ｄｎａ－ｐｋ阻害剤としてのピリミドイミダゾル系化合物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040213757A1 (en) 2003-04-23 2004-10-28 Wyeth Holdings Corporation Water soluble wortmannin derivatives
US20060106022A1 (en) 2004-09-24 2006-05-18 Jian Liu Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
WO2008016669A2 (en) 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
US20090023724A1 (en) 2006-10-19 2009-01-22 Deborah Sue Mortensen Heteroaryl compounds, compositions thereof, and methods of treatment therewith
WO2010068483A2 (en) 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use
WO2011097333A1 (en) 2010-02-03 2011-08-11 Signal Pharmaceuticals, Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE262026C (cg-RX-API-DMAC7.html)
US3507866A (en) 1967-08-08 1970-04-21 Merck & Co Inc 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation
US3567725A (en) 1968-11-20 1971-03-02 Merck & Co Inc Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones
US4317909A (en) 1980-03-24 1982-03-02 Sterling Drug Inc. Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones
US4294837A (en) 1980-03-28 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use
US4294836A (en) 1980-03-24 1981-10-13 Sterling Drug Inc. 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use
US4309537A (en) 1980-03-28 1982-01-05 Sterling Drug Inc. Production of imidazo[4,5-b]pyridin-2-ones or thiones
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
JPS63275582A (ja) 1987-05-02 1988-11-14 Naade Kenkyusho:Kk ２−アミノイミダゾ〔４，５−ｂ〕ピリジン誘導体の製造方法
DD262026A1 (de) 1987-07-10 1988-11-16 Akad Wissenschaften Ddr Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen
FR2643903A1 (fr) 1989-03-03 1990-09-07 Union Pharma Scient Appl Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux
US4963561A (en) 1990-02-28 1990-10-16 Sterling Drug Inc. Imidazopyridines, their preparation and use
TW274550B (cg-RX-API-DMAC7.html) 1992-09-26 1996-04-21 Hoechst Ag
DE19601627A1 (de) 1996-01-18 1997-07-24 Bayer Ag Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone
US6031105A (en) 1996-04-09 2000-02-29 Pfizer Inc Substituted pyridines
CN1167420C (zh) 1997-09-26 2004-09-22 赞塔里斯有限公司 用于调制丝氨酸/苏氨酸蛋白激酶功能的氮杂苯并咪唑类化合物
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
JP2003146987A (ja) 1999-05-31 2003-05-21 Dainippon Pharmaceut Co Ltd ２−アリールプリン−９−アセトアミド誘導体
JP3814125B2 (ja) 1999-06-02 2006-08-23 大日本住友製薬株式会社 ２−アリール−８−オキソジヒドロプリン誘導体からなる医薬
JP2002100363A (ja) 2000-09-25 2002-04-05 Mitsubishi Chemicals Corp リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池
JP2002167387A (ja) 2000-11-29 2002-06-11 Dainippon Pharmaceut Co Ltd ２−（７，８−ジヒドロ−８−オキソ−９ｈ−プリン−９−イル）酢酸誘導体
US20050033048A1 (en) 2000-12-12 2005-02-10 Rajagopal Bakthavatchalam Spiro[isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines
WO2002076954A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
MXPA04002067A (es) 2001-09-04 2004-06-07 Boehringer Ingelheim Pharma Nuevas dihidropteridinonas, procedimientos para su preparacion y su uso como medicamento.
CA2462441A1 (en) 2001-10-18 2003-04-24 Pier F. Cirillo 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
US7247621B2 (en) 2002-04-30 2007-07-24 Valeant Research & Development Antiviral phosphonate compounds and methods therefor
JP2005530759A (ja) 2002-05-06 2005-10-13 ジェネラブズ テクノロジーズ インコーポレーティッド Ｃ型肝炎ウイルス感染症を治療するためのヌクレオシド誘導体
WO2004042002A2 (en) 2002-08-05 2004-05-21 University Of Massachusetts Compounds for modulating rna interference
EP1556053A4 (en) 2002-10-31 2006-04-19 Amgen Inc ANTI-INFLAMMATORY AGENTS
CA2512646A1 (en) 2003-01-17 2004-08-05 Warner-Lambert Company Llc 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation
DK1599478T3 (da) 2003-02-26 2007-09-17 Boehringer Ingelheim Pharma Dihydropteridinoner, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemiddel
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
ES2906207T3 (es) 2003-05-30 2022-04-13 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
EP1641423B1 (en) 2003-06-26 2010-03-17 Merck Sharp & Dohme Corp. Benzodiazepine cgrp receptor antagonists
EP1750715A1 (en) 2004-06-04 2007-02-14 Icos Corporation Methods for treating mast cell disorders
DE102004029784A1 (de) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
WO2006001266A1 (ja) 2004-06-23 2006-01-05 Banyu Pharmaceutical Co., Ltd. ２－アリールプリン誘導体の製造方法
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
AU2005298637B8 (en) 2004-10-29 2012-12-06 Janssen Sciences Ireland Uc HIV inhibiting bicyclic pyrimidine derivatives
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
SE0403006D0 (sv) 2004-12-09 2004-12-09 Biovitrum Ab New compounds
WO2006065703A1 (en) 2004-12-13 2006-06-22 Sunesis Pharmaceuticals, Inc. Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as raf kinase inhibitors
PL1853588T3 (pl) 2005-02-16 2008-11-28 Astrazeneca Ab Związki chemiczne
WO2006091737A1 (en) 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
CA2604161A1 (en) 2005-04-05 2006-10-12 Pharmacopeia, Inc. Purine and imidazopyridine derivatives for immunosuppression
CA2629245C (en) 2005-11-21 2016-07-12 Novartis Ag Neuroendocrine tumor treatment
US20090281075A1 (en) 2006-02-17 2009-11-12 Pharmacopeia, Inc. Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors
CA2662677C (en) 2006-09-05 2016-05-31 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
US20100144738A1 (en) 2006-09-05 2010-06-10 William Bornmann Inhibitors of c-met and uses thereof
AR063142A1 (es) 2006-10-04 2008-12-30 Pharmacopeia Inc Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen.
US7902187B2 (en) 2006-10-04 2011-03-08 Wyeth Llc 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression
MX2009004019A (es) 2006-10-19 2009-06-19 Signal Pharm Llc Compuestos heteroarilo, composiciones de los mismos, y uso de los mismos como inhibidores de proteina cinasa.
CA2709784A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
US8110578B2 (en) * 2008-10-27 2012-02-07 Signal Pharmaceuticals, Llc Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway
JP5590040B2 (ja) * 2008-11-12 2014-09-17 アリアド・ファーマシューティカルズ・インコーポレイテッド キナーゼ阻害剤としてのピラジノピラジンおよび誘導体
KR20120091240A (ko) * 2009-10-26 2012-08-17 시그날 파마소티칼 엘엘씨 헤테로아릴 화합물의 합성 및 정제 방법
US20120028972A1 (en) 2010-07-30 2012-02-02 Lilly Wong Biomarker assays for detecting or measuring inhibition of tor kinase activity
MX2014001246A (es) 2011-08-03 2014-06-11 Signal Pharm Llc Identificación del perfil de la expresión génica como biomarcador predictivo del estatus de lkb1.
SG11201402766UA (en) 2011-12-02 2014-06-27 Signal Pharm Llc PHARMACEUTICAL COMPOSITIONS OF 7-(6-(2-HYDROXYPROPAN-2-YL)PYRIDIN-3-YL)-1-((TRANS)-4-METHOXYCYCLOHEXYL)-3,4-DIHYDROPYRAZINO [2,3-<i>B</i>]PYRAZIN-2(1<i>H</i>)-ONE, A SOLID FORM THEREOF AND METHODS OF THEIR USE

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040213757A1 (en) 2003-04-23 2004-10-28 Wyeth Holdings Corporation Water soluble wortmannin derivatives
US20060106022A1 (en) 2004-09-24 2006-05-18 Jian Liu Imidazo[4,5-b]pyrazinone inhibitors of protein kinases
WO2008016669A2 (en) 2006-08-02 2008-02-07 Cytokinetics, Incorporated Certain chemical entities, compositions and methods
US20090023724A1 (en) 2006-10-19 2009-01-22 Deborah Sue Mortensen Heteroaryl compounds, compositions thereof, and methods of treatment therewith
WO2010068483A2 (en) 2008-11-25 2010-06-17 University Of Rochester Mlk inhibitors and methods of use
WO2011097333A1 (en) 2010-02-03 2011-08-11 Signal Pharmaceuticals, Llc Identification of lkb1 mutation as a predictive biomarker for sensitivity to tor kinase inhibitors

Also Published As

Publication number Publication date
US20170027932A1 (en) 2017-02-02
ZA201402771B (en) 2015-11-25
SG10201505102WA (en) 2015-07-30
TWI629983B (zh) 2018-07-21
US9937170B2 (en) 2018-04-10
US20180235960A1 (en) 2018-08-23
NZ710245A (en) 2016-11-25
CN107157990B (zh) 2020-01-07
IL281180A (en) 2021-04-29
TW201733585A (zh) 2017-10-01
NZ623759A (en) 2016-05-27
CN107157990A (zh) 2017-09-15
MX2020004689A (es) 2021-07-09
KR20140092336A (ko) 2014-07-23
IN2014CN02887A (cg-RX-API-DMAC7.html) 2015-07-03
CA2852921C (en) 2023-10-10
MX357833B (es) 2018-07-26
IL281180B (en) 2022-10-01
BR112014009755A2 (pt) 2017-04-25
CA2852921A1 (en) 2013-04-25
WO2013059396A3 (en) 2013-08-22
CN103998036A (zh) 2014-08-20
TW201733584A (zh) 2017-10-01
EP3466423B1 (en) 2021-07-28
SG10201912850WA (en) 2020-02-27
PH12014500869A1 (en) 2014-06-30
EA201490814A1 (ru) 2014-09-30
MX373925B (es) 2020-07-10
WO2013059396A2 (en) 2013-04-25
ES2751921T3 (es) 2020-04-02
ZA201407793B (en) 2016-08-31
ES2894958T3 (es) 2022-02-16
TW202034922A (zh) 2020-10-01
HK1243919A1 (zh) 2018-07-27
BR112014009755B1 (pt) 2022-09-13
IL256828B (en) 2021-04-29
JP2017039780A (ja) 2017-02-23
SG11201401630SA (en) 2014-05-29
IL232128A0 (en) 2014-05-28
JP6360136B2 (ja) 2018-07-18
TWI708605B (zh) 2020-11-01
EP2768500B1 (en) 2019-08-21
JP2014530861A (ja) 2014-11-20
EA201890768A2 (ru) 2018-08-31
TWI713752B (zh) 2020-12-21
US9493466B2 (en) 2016-11-15
IL281180B2 (en) 2023-02-01
IL256828A (en) 2018-03-29
US20220273650A1 (en) 2022-09-01
MX384385B (es) 2025-03-14
JP2021107461A (ja) 2021-07-29
US20130102613A1 (en) 2013-04-25
EP2768500A2 (en) 2014-08-27
EP3466423A2 (en) 2019-04-10
EP3659599A1 (en) 2020-06-03
EP3466423A3 (en) 2019-07-03
JP2020169203A (ja) 2020-10-15
UA115319C2 (uk) 2017-10-25
US11166950B2 (en) 2021-11-09
TWI758746B (zh) 2022-03-21
CN103998036B (zh) 2017-05-31
EA030664B1 (ru) 2018-09-28
IL232128B (en) 2018-01-31
EP3659599B1 (en) 2022-12-21
MX2014004775A (es) 2015-01-16
EA034512B1 (ru) 2020-02-14
EA201890768A3 (ru) 2018-12-28
MX348566B (es) 2017-06-20
TW201318626A (zh) 2013-05-16
MY183661A (en) 2021-03-05
JP2018162286A (ja) 2018-10-18

Similar Documents

Publication Publication Date Title
KR101978537B1 (ko) Tor 키나제 억제제를 사용한 암의 치료
AU2014223501A1 (en) Treatment of cancer with TOR kinase inhibitors
AU2012318272B2 (en) Treatment of cancer with TOR kinase inhibitors
AU2015200318B2 (en) Treatment of cancer with TOR kinase inhibitors
HK40006113A (en) Treatment of cancer with tor kinase inhibitors
HK40006113B (en) Treatment of cancer with tor kinase inhibitors
HK1243919B (zh) 利用tor激酶抑制剂治疗癌症
HK1195511A (en) Treatment of cancer with tor kinase inhibitors
HK1195511B (en) Treatment of cancer with tor kinase inhibitors

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140514

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20170929

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20181130

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20190308

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20190508

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20190508

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20220415

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20230418

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20240402

Start annual number: 6

End annual number: 6